Mustang Bio Stock Today
| MBIO Stock | USD 1.41 0.01 0.71% |
PerformanceVery Weak
| Odds Of DistressHigh
|
Mustang Bio is selling at 1.41 as of the 17th of March 2025; that is 0.71 percent increase since the beginning of the trading day. The stock's open price was 1.4. Mustang Bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of August 2017 | Category Healthcare | Classification Health Care |
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. The company has 1.91 M outstanding shares of which 118.22 K shares are now shorted by private and institutional investors with about 0.29 trading days to cover. More on Mustang Bio
Moving against Mustang Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Mustang Stock Highlights
| CEO, President | Manuel MD | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMustang Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Mustang Bio's financial leverage. It provides some insight into what part of Mustang Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Mustang Bio (MBIO) is traded on NASDAQ Exchange in USA. It is located in 95 Sawyer Road, Waltham, MA, United States, 02453 and employs 80 people. Mustang Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.89 M. Mustang Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.91 M outstanding shares of which 118.22 K shares are now shorted by private and institutional investors with about 0.29 trading days to cover.
Mustang Bio currently holds about 107.37 M in cash with (49.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.01.
Check Mustang Bio Probability Of Bankruptcy
Ownership AllocationMustang Bio secures 12.77 % of its outstanding shares held by insiders and 4.89 % owned by institutional investors.
Check Mustang Ownership Details
Mustang Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Macquarie Group Ltd | 2024-09-30 | 8 K | |
| Ubs Group Ag | 2024-09-30 | 5.6 K | |
| Harbour Investments, Inc. | 2024-09-30 | 3.8 K | |
| Cwm, Llc Duplicate | 2024-09-30 | 634 | |
| Bank Of America Corp | 2024-09-30 | 330 | |
| Jpmorgan Chase & Co | 2024-09-30 | 266 | |
| Activest Wealth Management | 2024-09-30 | 133 | |
| Sbi Securities Co Ltd | 2024-12-31 | 114 | |
| Group One Trading, Lp | 2024-09-30 | 56.0 | |
| Geode Capital Management, Llc | 2024-09-30 | 245.5 K | |
| Blackrock Inc | 2024-09-30 | 83.3 K |
Mustang Bio Historical Income Statement
Mustang Stock Against Markets
Mustang Bio Corporate Management
| Kerry BBA | VP Operations | Profile | |
| Lynn MS | VP Affairs | Profile | |
| Eliot CPA | Interim Officer | Profile | |
| Richard MS | Head Development | Profile | |
| Matthew JD | VP Counsel | Profile | |
| Bruce MD | Senior Development | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mustang Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Mustang Stock, please use our How to Invest in Mustang Bio guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mustang Bio. If investors know Mustang will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mustang Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mustang Bio is measured differently than its book value, which is the value of Mustang that is recorded on the company's balance sheet. Investors also form their own opinion of Mustang Bio's value that differs from its market value or its book value, called intrinsic value, which is Mustang Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mustang Bio's market value can be influenced by many factors that don't directly affect Mustang Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mustang Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mustang Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mustang Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.